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provide a tool to monitor the effect of novel medical treatments developed to reduce 34 
progression of distal disease.  35 
 36 
Body of editorial: 37 
The fields of paediatric cardiology and cardiothoracic surgery have made significant 38 
progress over the last fifty years but despite this there are some conditions which are 39 
still extremely resistant to treatment; pulmonary vein stenosis is one such lesion. 40 
Over the last five years there have been significant advances in our understanding of 41 
this disease and the team from Hospital for Sick Children in Toronto should be 42 
commended for their dedication into leading research in this particular field.  43 
 44 
Pulmonary vein stenosis is a life-threatening and challenging condition where the 45 
pulmonary veins are narrowed, resulting in obstruction of blood flowing back to the 46 
heart. It is often progressive, leading to generalised narrowing of the pulmonary 47 
veins upstream (distal) from the original site of obstruction and in some cases atresia 48 
may develop(1). This results in raised pulmonary venous pressure and pulmonary 49 
oedema, often leading to progressive pulmonary hypertension, right heart failure and 50 
death. Development of a major venous collateral network can occur and may be 51 
associated with improved outcome(1). Neoproliferation of cells(2) is responsible for 52 
the pulmonary venous narrowing but the exact pathophysiology remains unknown.  53 
 54 
Our lack of understanding of this condition likely accounts for why there are so many 55 
different types of surgical and catheter interventions; yet still we have not managed 56 
to find the optimal treatment. Introduction of the “sutureless” surgical technique has 57 
made some progress in treating proximal disease(3;4), but results remain 58 
disappointing when there is distal disease. An aggressive, early combination of both 59 
catheter and surgical interventional strategies may be the most effective, particularly 60 
in young and small patients, where the disease process can be particularly active(5). 61 
However, due to the progressive nature of pulmonary vein stenosis, the most 62 
important prerequisite for successful outcome is to achieve complete abolition of the 63 
stenosis at an early stage and before there is progression of the disease distally. The 64 
optimal initial strategy is likely to depend upon local expertise, but repeated 65 
interventions, both surgical and catheter should be contemplated. Mortality and 66 
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morbidity are substantial and even balloon angioplasty has recently been associated 67 
with significant risk of neurological injury(6). 68 
 69 
An understanding of the limitations of imaging modalities is vital when diagnosing 70 
proximal pulmonary vein stenosis. Diagnosis can be particularly difficult with 71 
echocardiography alone. Indeed in 26% of cases with primary pulmonary vein 72 
stenosis, the stenosis were not diagnosed on echocardiogram but rather at cardiac 73 
catheterisation or surgery(1). Close observation and a high index of suspicion is 74 
required, with further imaging by computerised tomography, cardiac magnetic 75 
resonance imaging or angiography recommended if there is any concern of 76 
obstruction. Cardiac magnetic resonance imaging is particularly helpful as it not only 77 
delineates pulmonary venous anatomy, but also blood flow redistribution in the 78 
pulmonary veins and arteries(7). 79 
 80 
But how do we know when there is distal disease? It can be very difficult to decide 81 
whether the upstream vessels are involved in the disease process; decisions are 82 
often made after subjective interpretation of angiography performed in the cardiac 83 
catheterisation laboratory. It is vital to diagnose distal disease as this will influence 84 
whether surgical interventions, that only really treat proximal disease, are likely to be 85 
beneficial. It can also help predict long-term outcome. In this issue Lo Rito and 86 
colleagues (8) have suggested a novel technique to make objective measurements 87 
of the distal pulmonary venous vasculature using cardiac magnetic resonance 88 
imaging and computerised tomography thereby potentially diagnosing patients with 89 
diffuse distal disease. This is crucial for identifying patients more likely to respond to 90 
current surgical treatments and those that may be candidates for more novel medical 91 
therapies for distal disease. This novel and quite complex approach may also be 92 
used to quantify response to therapies over time. It would have been interesting to 93 
see a comparison of computerised tomography and cardiac magnetic resonance 94 
imaging in measuring this new index. Furthermore there would have been additional 95 
utility in developing a “cut-off” value of upstream total cross sectional area index 96 
defined below which surgical intervention may be considered futile.   97 
 98 
Treatment of distal stenosis is not amenable to surgical or catheter intervention and 99 
so attention has turned to novel medical therapies to treat distal disease. Previous 100 
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studies have investigated the mechanisms responsible for progression of pulmonary 101 
vein stenosis. Histological studies have shown a variable manifestation of intimal and 102 
medial interstitial fibromuscular proliferation, together with fibrotic displacement of 103 
the muscle bundles in the venous wall. This results in occlusion of the lumen of one 104 
or more of the pulmonary veins connecting the lungs to the left atrium. Most 105 
commonly, the thickening of intimal tissue occurs at the junction where the left atrium 106 
meets the pulmonary vein; the narrowing then extends along the pulmonary vein 107 
towards the hilum of the lung. Various cell types have been proposed as the source 108 
of neoproliferation.  In 2000, Sadr(9) studied pulmonary venous tissue from 10 109 
children presenting with congenital pulmonary vein stenosis in a normally connected 110 
heart. There was no evidence for thrombosis, inflammation or fibrosis, however there 111 
was evidence of myofibroblastic proliferation. Myofibroblasts are a progenitor cell for 112 
myocytes and fibroblasts, and retain the ability to differentiate into either cell type 113 
depending upon environmental factors. They proposed that congenital pulmonary 114 
vein stenosis could be treated with agents that arrest or eradicate the 115 
neoproliferative process such as radiation, chemotherapy or gamma interferon. A 116 
subsequent study in 2006 by Riedlinger(10) showed that expression of various 117 
receptor tyrosine kinases and some ligands raised the possibility of an autocrine or 118 
paracrine role for these proteins in the pathogenesis of the intimal occlusive lesion 119 
seen in pulmonary vein stenosis. Clearly, understanding these processes would 120 
ultimately help develop treatments for pulmonary vein stenosis. Myofibroblastic 121 
proliferation also occurs in desmoid tumors of infancy and this led Rehman et al(11) 122 
to undertake a chemotherapeutic trial using vincristine and methotrexate in infants 123 
and children with progressive multivessel intraluminal pulmonary vein stenosis: 124 
success was limited. 125 
 126 
Animal models have in the past been used to investigate the pathological changes in 127 
pulmonary vasculature that occur with pulmonary venous obstruction. 128 
LaBourene(12) in 1990 banded the pulmonary veins in piglets and studied 129 
haemodynamic, histological and biochemical changes in the pulmonary vasculature 130 
over time. From the Toronto group, Kato et al(13) used a similar animal model in six 131 
piglets that underwent bilateral pulmonary venous banding and showed endothelial-132 
mesenchymal transition. Tissues from vessels upstream of the banded pulmonary 133 
veins were associated with robust expression of transforming growth factor (TGF-β). 134 
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Zhu et al(14) again used the piglet model to investigate the effect of losartan on the 135 
progression of the stenotic process. They hypothesised that losartan has an 136 
inhibitory effect on TGF-β and hence may modify the progressive stenosis seen in 137 
distal veins. They found that losartan significantly lowered the ratio of pulmonary 138 
artery/ systemic blood pressure and diminished intimal hyperplasia. The mechanism 139 
as to why it helped remains unclear. There was no difference in TGF-β levels 140 
between the losartan and non-losartan groups however there was a difference in VE-141 
caderin levels which they thought was indicative of diminished endothelial integrity. 142 
Clearly there is still much work to be done in establishing the pathological pathways 143 
that lead to progressive distal venous obstruction and translating this to humans. 144 
However, this is extremely exciting and innovative work investigating the potential for 145 
post-interventional therapies to reduce the effect of distal disease. This would be 146 
particularly important in patients considered at high risk of developing post-operative 147 
stenosis. Lo Rito’s imaging techniques may help identify such high risk groups and 148 
monitor the effect of novel therapies. It would be extremely interesting to see 149 
whether losartan has a role in reversing established disease and hopefully the 150 
research team will go on to investigate this. Future work is likely to involve clinical 151 
trials in humans and, due to the rarity of this disease; this is likely to be multi-152 
institutional and multi-national. We sincerely hope that the paediatric cardiac 153 
community can come together to make such trials a reality. 154 
 155 
In summary, pulmonary vein stenosis is frequently a progressive disease leading to 156 
generalised narrowing of the pulmonary veins and in some cases atresia. The best 157 
way to prevent progression is to identify and treat the stenosis in the first place so 158 
distal disease does not have the chance to occur. In this issue, the team from 159 
Toronto proposes a new index of pulmonary vein cross sectional area measured at 160 
cardiac magnetic resonance and computerised tomography as a tool to detect 161 
patients that are likely to have distal disease and hence worse prognosis. They have 162 
previously proposed losartan as a medical treatment which may have a role in 163 
preventing distal disease from occurring. This is an exciting development which if 164 
confirmed would represent a real advance in therapeutic options. So, are we at a 165 
stage where we can prevent progression of pulmonary vein stenosis? There is no 166 
doubt we are closer, however there is still much more work needed and clearly 167 
collaborative medical trials are the optimal way to progress. For the present, 168 
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treatment of established distal pulmonary venous disease remains an extremely 169 
challenging and resistant condition to treat. 170 
 171 
 172 
 173 
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